Rewards Hub 
UnitedHealth Group (UNHUSDT) is the largest private healthcare company on the planet, with $447.6 billion in annual revenue and 49.8 million insured lives. It has been a cornerstone of the Dow Jones Industrial Average, a Buffett-endorsed holding, and arguably the single most important stock in U.S. healthcare for the past decade. It has also lost roughly half its value in the past year.
The FY2025 results reported on January 27, 2026 showed $447.6 billion in revenue (up 12% YoY), but earnings from operations fell to $19.0 billion, including a $2.8 billion charge covering cyberattack costs, divestitures, restructuring, and workforce reductions. Adjusted EPS came in at $16.35 for the full year and $2.11 for Q4, barely meeting the $2.12 consensus.
The real shock was the 2026 outlook: revenue greater than $439 billion, a 2% year-over-year decline and the first time in a decade UNH has guided for falling revenue. The stock plunged nearly 20% in a single session, and combined with a year of DOJ investigations, CEO departures, and Medicare funding pressure, UNH now trades around $280, down roughly 55% from its all-time high.
Analyst consensus remains Buy, with an average target around $373 across 24 analysts, implying roughly 33% upside. But this is no longer a defensive blue-chip. It is a restructuring story.
The Business in 60 Seconds
UnitedHealth Group was founded in 1977 and is headquartered in Minnetonka, Minnesota. Stephen Hemsley returned as CEO in May 2025 after Andrew Witty's resignation, bringing back the architect of the company's integrated care model. The company operates through two interconnected businesses:
UnitedHealthcare (~77% of revenue): The nation's largest health insurer, serving 49.8 million people across employer-sponsored plans, individual coverage, Medicare Advantage, and Medicaid. Full-year 2025 revenue was $344.9 billion, up 16% year over year. However, operating margin collapsed from 5.2% in 2024 to 2.7% in 2025, driven by Medicare funding cuts and accelerating medical costs. Medicare Advantage is the largest single revenue contributor at roughly $139 billion annually.
Optum (~60% of revenue, with overlap): The technology, pharmacy, and care delivery arm that differentiates UNH from pure-play insurers. Optum breaks into three sub-segments: Optum Health (care delivery, serving 123+ million consumers), Optum Rx (pharmacy benefit management), and Optum Insight (data analytics and technology services). Optum revenue was $270.6 billion in FY2025, up 7% year over year.
The integrated model is what made UNH a compounding machine for over a decade: the insurer (UnitedHealthcare) pays claims to providers that are increasingly owned or managed by Optum, creating a vertically integrated system that captures value at every stage of the healthcare chain. This is also what draws the most regulatory scrutiny.
What's Moving the Stock
The DOJ investigation is the primary overhang. UnitedHealth confirmed in July 2025 that it is cooperating with bothcriminal and civil Department of Justice investigations into its Medicare Advantage billing practices. The probes focus on whether the company inflated patient diagnoses to trigger higher reimbursements from Medicare, including allegations that diagnoses were added during in-home nurse assessments without physician confirmation. This investigation targets Medicare Advantage, which is UNH's single largest revenue segment.
Medicare Advantage rates for 2027 were proposed nearly flat. On January 26, 2026, the Centers for Medicare & Medicaid Services proposed a net rate increase of just 0.09% for Medicare Advantage plans in FY2027, effectively a cut when adjusted for medical inflation. The timing, one day before earnings, amplified the sell-off. The V28 coding transition also represents a $6 billion revenue headwind for 2026.
The medical care ratio is elevated. The adjusted medical care ratio (the percentage of premiums spent on actual medical claims) rose to 88.9% in FY2025, up from 85.5% in 2024. This 340 basis point deterioration reflects rising utilization trends, Medicare funding cuts, and Inflation Reduction Act impacts. For 2026, management guided MCR to 88.8%, essentially flat, meaning margin recovery will be gradual.
Membership is declining intentionally. UNH expects to lose more than 3 million members in 2026 as it exits unprofitable Medicare Advantage markets and sheds low-margin Medicaid contracts. CFO Wayne DeVeydt described this as "right-sizing across the enterprise." Combined with divestitures of international operations (UK and South America), this produces the first revenue decline in a decade.
Leadership turbulence has been severe. The December 2024 murder of UnitedHealthcare CEO Brian Thompsonsparked public outrage against health insurers. CEO Andrew Witty resigned in May 2025. Stephen Hemsley's return was intended to stabilize the company, and early signals suggest a shift toward operational discipline over growth, pausing M&A and buybacks to shore up the balance sheet.
Warren Buffett bought the dip. Berkshire Hathaway purchased approximately 5 million UNH shares in Q2 2025, a significant vote of confidence from the most well-known value investor in the world. CEO Hemsley also personally bought 86,700 shares for $25 million.
The Bull Case vs. The Bear Case
|
|
Bulls Say
|
Bears Say
|
|
Valuation
|
Trading at roughly 13x forward earnings, the cheapest in over a decade. Buffett bought millions of shares. CEO bought $25M worth. 33% upside to analyst consensus.
|
Cheap for a reason. DOJ investigation could result in fines, operational restrictions, or forced structural changes. The stock may be a value trap.
|
|
Revenue decline
|
Intentional right-sizing. Exiting unprofitable markets improves mix. Revenue decline is temporary; management targets low double-digit growth by 2027.
|
First revenue decline in a decade signals structural pressure, not just a reset year. Membership losses of 3M+ are hard to reverse.
|
|
Medical care ratio
|
MCR guided to 88.8% for 2026, slight improvement from 88.9%. As unprofitable contracts are shed, margins should normalize.
|
MCR expanded 340 bps in one year. Medical cost trends are accelerating industry-wide. Aging population means higher utilization is structural, not cyclical.
|
|
DOJ investigation
|
Company emphasizes compliance record and favorable findings from prior CMS audits. Settlement is more likely than structural breakup. Mizuho analyst says market overreacts.
|
Criminal and civil probes are ongoing. Forced divestiture of Optum would destroy the integrated model. Even a settlement could mean billions in penalties and operational changes.
|
|
Optum moat
|
Optum serves 123M+ consumers across care delivery, pharmacy, and data analytics. The integrated model is nearly impossible to replicate at scale.
|
Optum's vertical integration is exactly what regulators are scrutinizing. PBM transparency rules could compress Optum Rx margins. Political risk on both sides of the aisle.
|
|
Demographics
|
10,000 Americans turn 65 daily. Medicare enrollment will grow for decades. UNH is the dominant MA player and will benefit from volume growth long-term.
|
Medicare funding is not keeping pace with cost of care. Government increasingly sees MA as overpaying private insurers relative to traditional Medicare.
|
|
Hemsley return
|
The architect of UNH's rise is back. Insiders are buying aggressively. "Back to Basics" strategy prioritizes discipline over expansion.
|
Hemsley is managing a crisis, not leading growth. The company's reputation has been severely damaged by the Thompson murder, DOJ probe, and CEO departure.
|
The Numbers That Matter
FY2025 revenue: $447.6 billion (+12% YoY). UnitedHealthcare contributed $344.9 billion (+16%) and Optum contributed $270.6 billion (+7%). Note that revenue overlap exists between the two segments due to inter-company transactions.
Q4 2025 revenue: $113.2 billion, missing the $114.96 billion consensus by roughly $1.7 billion. Adjusted EPS of $2.11 essentially matched the $2.12 estimate. The near-miss on both metrics amplified the sell-off because the forward guidance was so weak.
FY2025 earnings from operations: $19.0 billion, including a $2.8 billion one-time charge. Adjusted earnings from operations were $21.7 billion. Operating cash flow was $19.7 billion, representing 1.5x net income.
FY2026 outlook: revenue greater than $439 billion (approximately 2% decline), earnings from operations greater than $24 billion, and adjusted EPS greater than $17.75. Analysts had been expecting $454.6 billion in revenue, so the guidance represented a roughly $15 billion shortfall versus expectations.
Medical care ratio: 88.9% adjusted for FY2025, up from 85.5% in FY2024. Guided at 88.8% for FY2026, a marginal 10 basis point improvement. This ratio is the most important profitability metric in health insurance.
Membership: 49.8 million served in 2025, with more than 3 million members expected to decline in 2026 across commercial, Medicare Advantage, and Medicaid segments.
Stock price context: approximately $280 in late February 2026, down roughly 55% from the all-time high. Market cap is approximately $260 billion. Dividend yield is approximately 2.8%. Next earnings: approximately April 22, 2026.
Key Risk Factors for Traders
The DOJ investigation is open-ended. Both criminal and civil probes are active, with no clear timeline for resolution. Outcomes could range from a manageable settlement to significant fines, operational restrictions, or in a worst case, forced divestiture of parts of Optum. The investigation specifically targets the Medicare Advantage billing practices that generate UNH's largest revenue stream.
Medicare Advantage rate pressure is structural. The proposed near-flat 2027 rate increase suggests the government increasingly views MA as overpaying private insurers. If this trend continues, UNH's most profitable growth engine faces ongoing margin compression. The V28 coding transition is a $6 billion headwind in 2026 alone.
Medical cost trends are accelerating. The 340 basis point MCR increase in 2025 was not a one-time event. Healthcare utilization is rising across the industry, driven by an aging population, post-pandemic deferred care catch-up, and new high-cost therapies (including GLP-1 drugs). If cost trends worsen faster than premium increases, margins could deteriorate further.
Political risk is elevated on both sides. Pharmacy benefit managers like Optum Rx are a bipartisan political target. Transparency rules, potential regulation of PBM rebate structures, and public anger at health insurers (intensified after the Thompson murder) create an unpredictable regulatory environment.
Revenue decline is a first in a decade. Even though management describes the 2026 decline as intentional right-sizing, the market is unaccustomed to UNH shrinking. If the "temporary" revenue dip becomes a multi-year trend due to continued membership losses and Medicare rate pressure, the stock's valuation re-rating thesis falls apart.
This is a 20% single-day mover. UNH dropped nearly 20% on January 27 after earnings and guidance. For a stock of this size and defensive reputation, that kind of volatility is historically unusual and signals that institutional positioning can unwind rapidly when the thesis breaks.
Trade UNH on Phemex
UnitedHealth Group is available as a TradFi futures contract on Phemex, tradable 24/7 using the same USDT-margined interface you already know from crypto futures.
UNH may seem like an unusual pick alongside tech and crypto-adjacent names, but that is exactly the point. This is the kind of stock that moves 10-20% on earnings, DOJ headlines, and Medicare rate announcements, catalysts that often break outside regular market hours. Phemex TradFi gives you around-the-clock access to trade the reaction, not wait for it.
Check the Futures Events Center for current zero-fee campaigns and trading rewards on TradFi pairs.
Bottom Line
UnitedHealth Group is navigating the most challenging period in its history. A DOJ investigation, Medicare rate pressure, accelerating medical costs, leadership turbulence, and the first revenue decline in a decade have driven the stock down 55% from its highs. At 13x forward earnings with Buffett backing and aggressive insider buying, the valuation case is compelling for long-term investors who believe the integrated model survives intact. For traders, UNH offers event-driven volatility that rivals anything in tech, with earnings, DOJ developments, and Medicare rate decisions all serving as near-term catalysts. The question is whether 2026 is a reset year or the beginning of a structural unwind for America's healthcare giant.
This article is for educational purposes only and does not constitute financial or investment advice. TradFi futures are high-risk derivative products. Leverage amplifies both gains and losses. Please evaluate your risk tolerance carefully before trading.
